The recent decline in stock price could raise concerns from investors as the firm closed today at a share price of 1180.0 on 48721.000 in volume. The company directors and management have failed to build on market volatilities in March. However, diversifying your overall positions with Compugen Ltd may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 5.6356. The very high volatility is mostly attributed to the latest market swings and not very good earning reports from some ot the Compugen Ltd partners. This diagnostics interface makes it easy to digest most current publicly released information about Compugen Ltd as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Compugen Ltd price relationship with some important fundamental indicators such as market cap and management efficiency. Check also Trending Equities.
The company recorded loss per share of 0.41. Compugen Ltd had not issued any dividends in recent years. Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. Compugen Ltd operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 89 people. For more info on COMPUGEN please contact Anat CohenDayag at 972 3 765 8585 or go to http://www.cgen.com.
Compugen Ltd Alerts
Compugen Ltd is not yet fully synchronised with the market data
The company reported revenue of 17.8M. Net Loss for the year was (22.6M) with profit before overhead, payroll, taxes, and interest of 16.77M.
COMPUGEN has accumulated about 45.07M in cash with (13.29M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75.
The company currently falls under 'Small-Cap' category with current market capitalization of 738.98M.
The company has Profit Margin (PM) of (126.96) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (130.49) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.3.
Compugen Ltd has return on total asset (ROA) of (31.58) % which means that it has lost $31.58 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (67.93) % meaning that it generated substantial loss on money invested by shareholders.